ETHACRYNATE SODIUM FOR INJECTION USP POWDER FOR SOLUTION

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

ETHACRYNIC ACID (ETHACRYNATE SODIUM)

Disponible depuis:

STERIMAX INC

Code ATC:

C03CC01

DCI (Dénomination commune internationale):

ETACRYNIC ACID

Dosage:

50MG

forme pharmaceutique:

POWDER FOR SOLUTION

Composition:

ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50MG

Mode d'administration:

INTRAVENOUS

Unités en paquet:

1VIAL

Type d'ordonnance:

Prescription

Domaine thérapeutique:

LOOP DIURETICS

Descriptif du produit:

Active ingredient group (AIG) number: 0101703001; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2017-11-02

Résumé des caractéristiques du produit

PRODUCT MONOGRAPH
Intravenous
Pr
ETHACRYNATE SODIUM FOR INJECTION USP
Lyophilized powder for injection, 50 mg equivalent to ethacrynic acid
PHARMACOLOGICAL CLASSIFICATION
Saluretic-Diuretic Agent
SteriMax Inc.
Date of Preparation:
2770 Portland Drive
November 1, 2017
Oakville, ON L6H 6R4
Control No. 204211
PRODUCT MONOGRAPH
Intravenous
Pr
ETHACRYNATE SODIUM FOR INJECTION USP
Lyophilized powder for injection, 50 mg equivalent to ethacrynic acid
PHARMACOLOGICAL CLASSIFICATION
Saluretic-Diuretic Agent
ACTION AND CLINICAL PHARMACOLOGY
Ethacrynic acid is a saluretic-diuretic agent with marked potency and
rapid onset of action. It is
chemically unrelated to other diuretics. Patients with congestive
heart failure (including acute
pulmonary edema), renal edema, hepatic cirrhosis with ascites, and
other conditions involving
fluid retention have responded well to ethacrynic acid.
Ethacrynic acid has the following major characteristics:
(1) WATER AND ELECTROLYTE EXCRETION may be increased several times
over that observed with
thiazide diuretics. The urinary output is usually dose-dependent and
related to the magnitude of
fluid accumulation.
(2) ELECTROLYTE EXCRETION PATTERN DIFFERS FROM THAT OF THIAZIDES.
Initially, sodium and chloride
excretion is usually substantial, and chloride loss exceeds that of
sodium. With prolonged
therapy, chloride excretion declines, and potassium and hydrogen ion
excretion may increase.
In patients with increased diuresis excessive amounts of potassium may
be excreted.
Ethacrynic acid is effective whether or not there is clinical acidosis
or alkalosis.
(3) RAPID ONSET OF ACTION usually is observed within 5 minutes after
an intravenous injection.
(4) SULFHYDRYL BINDING PROPENSITY differs in certain respects from
that of the organomercurials.
Its mode of action is not by carbonic anhydrase inhibition.
(5) MULTIPLE SITES OF ACTION. Ethacrynic acid acts on the proximal and
distal portions of the
tubule, and also on the ascending limb of the loop of Henle.
INDICATIONS AND CLINICAL USE
Ethacrynate So